Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
Key facts
- Where
- Anderson, Baton Rouge, Boardman, Boston, Bowling Green, Camp Hill, Columbus, Coral Gables, Dallas, Fargo, Hollywood, Indianapolis, Irvine, Katy, Los Angeles, Louisville, Mayfield Heights, Metairie, Mill Creek, Mt. Pleasant, Murfreesboro, New York, Northridge, Phoenix, Plainfield, Prosper, Reno, Rocklin, Saint Joseph, San Antonio, Savannah, Seattle, and Spokane, United StatesSee the 34 sites
- Phase
- Phase 2
Where in United States
- Palmetto Clinical Trial ServicesAnderson, United StatesNo longer taking part
- DelRicht LLCBaton Rouge, United StatesNo longer taking part
- Optima ResearchBoardman, United StatesNo longer taking part
- Beth Israel Deaconess Medical CenterBoston, United StatesNo longer taking part
- Equity Medical LLC (Kentucky)Bowling Green, United StatesNo longer taking part
- Best Skin Research, LLCCamp Hill, United StatesNo longer taking part
- ClinOhio Research ServicesColumbus, United StatesNo longer taking part
- Florida Academic Dermatology CenterCoral Gables, United StatesNo longer taking part
- Dermatology Treatment and Research CenterDallas, United StatesNo longer taking part
- Red River Research PartnersFargo, United StatesNo longer taking part
- Skin Care Research, LlcHollywood, United StatesNo longer taking part
- Indiana University School of MedicineIndianapolis, United StatesNo longer taking part
- First OC Dermatology Research, Inc.Irvine, United StatesNo longer taking part
- BRCR Global TexasKaty, United StatesNo longer taking part
- Wallace Medical Group, IncLos Angeles, United StatesNo longer taking part
- DS Research of Kentucky, LLCLouisville, United StatesNo longer taking part
- Apex Clinical Research CenterMayfield Heights, United StatesNo longer taking part
- Clinical Trials Management, LLCMetairie, United StatesNo longer taking part
- Frontier DermatologyMill Creek, United StatesNo longer taking part
- DelRicht ResearchMt. Pleasant, United StatesNo longer taking part
- International Clinical Research - Tennessee LLCMurfreesboro, United StatesNo longer taking part
- Equity MedicalNew York, United StatesNo longer taking part
- OptiSkin MedicalNew York, United StatesNo longer taking part
- Northridge Clinical TrialsNorthridge, United StatesNo longer taking part
- Medical Dermatology Specialists PhoenixPhoenix, United StatesNo longer taking part
- The Indiana Clinical Trials CenterPlainfield, United StatesNo longer taking part
- DelRicht ResearchProsper, United StatesNo longer taking part
- Skin Cancer and Dermatology InstituteReno, United StatesNo longer taking part
- NorCal Clinical ResearchRocklin, United StatesNo longer taking part
- Medisearch Clinical TrialsSaint Joseph, United StatesNo longer taking part
- Progressive Clinical ResearchSan Antonio, United StatesNo longer taking part
- Georgia Skin & Cancer ClinicSavannah, United StatesNo longer taking part
- University of Washington Medical CenterSeattle, United StatesNo longer taking part
- Dermatology Specialists of SpokaneSpokane, United StatesNo longer taking part
Trial details
- Who runs it
- Zura Bio Inc
- Trial code
- NCT06993610EU 2024-519736-17-00
- Record updated
- 19 October 2026
- Original description
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)Read full original descriptionShow less
A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Hidradenitis Suppurativa
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)
Inclusion: Male or female, 18 to 70 years of age; ≥6-month history of Hidradenitis suppurativa (HS); Total AN (abscess and inflammatory nodule) count ≥5; HS lesions in ≥2 distinct anatomical areas, at least one of which is Hurley Stage II or III.
Exclusion: Unable to tolerate subcutaneous drug administration; Presence of another inflammatory condition or a skin condition that may interfere with study assessments; Evidence or suspicion of active or latent tuberculosis; History of opportunistic, chronic, or recurrent infection requiring chronic antibiotic use, serious or life-threatening infection within 2 months, or had an infection requiring systemic antibiotics within 2 weeks; Draining tunnel count >20; Known to have immune deficiency or is immunocompromised; Has active systemic candidiasis.